Skip to main content
Top

Drugs

Issue 3/2026

Content (11 Articles)

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) in Uncontrolled Gout: Current Status and Future Directions

  • Open Access
  • Gout
  • Leading Article

Herbert S. B. Baraf, Naomi Schlesinger, Vibeke Strand

Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies

  • Open Access
  • Obesity
  • Review Article

Penelope Fotheringham, Richard G McGee, Ruby Chang, Debra Kennedy, David Simmons

First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?

Pamela Abdayem, Claudia Parisi, David Planchard

The Potential of Authorised Drugs to be Repurposed for the Treatment of Osteoarthritis: A Scoping Review of Clinical Studies

Michelle W. J. Heijman, Merel Hartog, Cornelia H. M. van den Ende, Calin D. Popa, Bart J. F. van den Bemt

Elamipretide: First Approval

Matt Shirley

Rilzabrutinib: First Approval

Arnold Lee

Zeprumetostat: First Approval

Susan J. Keam

Zongertinib: First Approval

  • NSCLC
  • AdisInsight Report

Arnold Lee

Remibrutinib: First Approval

Simon Fung

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images